COMP <GO>
EW vs STE // EV/EBITDA & P/E VALUATION
Edwards Lifesciences Corporation (NYSE) VS. STERIS plc (Ireland) (NYSE) • 15-METRIC TALLY: EW 8
— STE 5
▲ EV/EBITDA & P/E VALUATION LEADER: STE
LAST: $92.01 (-2.57%) • MKT CAP: $54.44B
valuation
35.1x
LAST: $227.12 (-2.16%) • MKT CAP: $22.63B
valuation
17.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EW VS. STE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EW | STE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 78.00% | 44.20% | +33.80 | EW | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.50% | 10.10% | +2.40 | EW | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 35.1x | 17.0x | +18.10 | STE | /valuation <GO> |
| Free Cash Flow Yield | 2.45% | 4.30% | -1.85 | STE | /fcf-yield <GO> |
| Operating Margin | 20.80% | 18.60% | +2.20 | EW | /operating-margins <GO> |
| Net Profit Margin | 17.70% | 13.20% | +4.50 | EW | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 8.70% | +2.80 | EW | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.07% | -1.07 | STE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.36 | 5.40 | +6.96 | EW | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | STE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.1 | 62.4 | +2.70 | EW | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.08 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 47.2x | 26.9x | +20.30 | STE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $54.44B | $22.63B | $31.80B | EW | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EW REV | STE REV | EW GROSS % | STE GROSS % | EW FCF | STE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.07B | $5.94B | 78.0% | 44.2% | $1.33B | $972.4M |
| FY 2024 | $5.44B | $5.46B | 79.5% | — | $289.9M | $778.0M |
| FY 2023 | $5.01B | $5.14B | — | — | $670.4M | $742.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EW // BETA 1.08
STE // BETA 1.08